HK1166077A1 - 作為 抑制劑的間苯二酚衍生物 - Google Patents

作為 抑制劑的間苯二酚衍生物

Info

Publication number
HK1166077A1
HK1166077A1 HK12106799.6A HK12106799A HK1166077A1 HK 1166077 A1 HK1166077 A1 HK 1166077A1 HK 12106799 A HK12106799 A HK 12106799A HK 1166077 A1 HK1166077 A1 HK 1166077A1
Authority
HK
Hong Kong
Prior art keywords
hsp90
resorcinol derivatives
inhibitors
hsp90 inhibitors
resorcinol
Prior art date
Application number
HK12106799.6A
Other languages
English (en)
Inventor
.布拉斯卡
.卡薩萊
.弗格森
.波盧奇
.祖科托
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1166077A1 publication Critical patent/HK1166077A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12106799.6A 2009-04-21 2012-07-11 作為 抑制劑的間苯二酚衍生物 HK1166077A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09158367 2009-04-21
PCT/EP2010/055026 WO2010121963A1 (en) 2009-04-21 2010-04-16 Resorcinol derivatives as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
HK1166077A1 true HK1166077A1 (zh) 2012-10-19

Family

ID=42270238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106799.6A HK1166077A1 (zh) 2009-04-21 2012-07-11 作為 抑制劑的間苯二酚衍生物

Country Status (9)

Country Link
US (1) US8993556B2 (zh)
EP (1) EP2421833B1 (zh)
JP (1) JP5731479B2 (zh)
CN (1) CN102438988B (zh)
AR (1) AR076645A1 (zh)
ES (1) ES2533954T3 (zh)
HK (1) HK1166077A1 (zh)
TW (1) TW201041856A (zh)
WO (1) WO2010121963A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011274369A1 (en) * 2010-07-02 2012-12-06 Ventana Medical Systems, Inc. Hapten conjugates for target detection
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
EP3013341A4 (en) * 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
CN109422690A (zh) * 2017-08-31 2019-03-05 浙江省化工研究院有限公司 一种制备1-烷基-3-烷基吡唑-5-甲酸酯的方法
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
CN109364045B (zh) * 2018-10-21 2020-08-21 郑州大学第一附属医院 一种热休克蛋白90抑制剂及在肝癌治疗方面的应用
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
MD3986890T2 (ro) 2019-06-18 2024-04-30 Pfizer Derivați de benzizoxazolsulfonamide
TWI771766B (zh) * 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶2 抑制劑
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2073284B1 (zh) * 1969-12-23 1973-07-13 Ferlux
DE2250343A1 (de) 1972-10-13 1974-04-18 Thiemann Chem Pharm Fab 4,6-disubstituierte resorcinverbindungen
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7538241B2 (en) 2003-12-26 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
JP2006306755A (ja) * 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするhsp90阻害剤
DK2118077T3 (en) * 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 ACTIVITY
GB0722680D0 (en) * 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use

Also Published As

Publication number Publication date
ES2533954T3 (es) 2015-04-16
WO2010121963A1 (en) 2010-10-28
US8993556B2 (en) 2015-03-31
EP2421833B1 (en) 2015-01-14
JP5731479B2 (ja) 2015-06-10
JP2012524743A (ja) 2012-10-18
EP2421833A1 (en) 2012-02-29
CN102438988A (zh) 2012-05-02
CN102438988B (zh) 2015-06-24
TW201041856A (en) 2010-12-01
US20120046266A1 (en) 2012-02-23
AR076645A1 (es) 2011-06-29

Similar Documents

Publication Publication Date Title
HK1166077A1 (zh) 作為 抑制劑的間苯二酚衍生物
HK1143367A1 (zh) 用作 抑制劑的喹唑啉-肟衍生物
HK1173142A1 (zh) -磺酰基- -氟代嘧啶酮衍生物
HK1172893A1 (zh) -氟嘧啶酮衍生物
IL219087A0 (en) Benzimidazole-imidazole derivatives
ZA201005435B (en) Oxim derivatives as hsp90 inhibitors
EP2486039A4 (en) HSP90 INHIBITORS SUITABLE PURE DERIVATIVES
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL213927A0 (en) Deoxyactagardine derivatives
IL218967A0 (en) Phenyloxadiazole derivatives as pgds inhibitors
HK1172894A1 (zh) -酰基- -氟嘧啶酮衍生物
HK1169623A1 (zh) 吡嗪並氮雜氧雜環庚烷衍生物
GB201009853D0 (en) HSP90 inhibitors
ZA201109536B (en) 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
GB0901898D0 (en) Dual calpain-ros inhibitors
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
EP2488183A4 (en) COMPOSITION FOR INHIBITING TGF-BETA WITH IMIDAZOPURINE DERIVATIVES
EP2512482A4 (en) DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
GB0901900D0 (en) Dual calpain-ros inhibitors
HK1173134A1 (zh) 取代的鹵代苯氧基苯甲酰胺衍生物
GB0808286D0 (en) Inhibitors of HSP90
IL213262A0 (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives